Aligos Therapeutics, Inc. (ALGS) shareholders
Close on Nov 16, 2026Market cap $20.73MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alyeska Fund GP, LLC Joint filing with Alyeska Investment Group, L.P. (9.99%), Anand Parekh (9.99%) | 530,000 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Sio Capital Management, LLC | 335,937 | 5.46% | 13G (passive) amendment | Dec 31, 2025 |
| Lawrence M. Blatt | 316,228 | 5.60% | 13D (active) | Jun 16, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALGS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 444,110 | 3.56% | $2.56M | – | 0.04% |
| Alyeska Investment Group, L.P. | 412,000 | 3.30% | $2.38M | – | 0.01% |
| Sio Capital Management, LLC | 327,237 | 2.62% | $1.89M | – | 0.31% |
| Marshall Wace, Llp | 246,579 | 1.97% | $1.42M | −20,556 | 0.00% |
| Woodline Partners LP | 177,362 | 1.42% | $1.02M | – | 0.00% |
| Vanguard Capital Management LLC | 175,543 | 1.41% | $1.01M | −2,719 | 0.00% |
| Baker Bros. Advisors LP | 83,055 | 0.67% | $479.23K | – | 0.00% |
| Hhlr Advisors, Ltd. | 76,247 | 0.61% | $439.95K | – | 0.05% |
| D. E. Shaw & Co., Inc. | 66,463 | 0.53% | $383.49K | +55,485 | 0.00% |
| UBS Group AG | 59,986 | 0.48% | $346.12K | +22,925 | 0.00% |
| Geode Capital Management, LLC | 47,173 | 0.38% | $272.32K | −2,802 | 0.00% |
| Jane Street Group, LLC | 32,402 | 0.26% | $186.96K | New | 0.00% |
| BlackRock, Inc. | 30,292 | 0.24% | $174.79K | +17,252 | 0.00% |
| Vanguard Fiduciary Trust Co | 28,612 | 0.23% | $165.09K | +175 | 0.00% |
| Dimensional Fund Advisors LP | 21,044 | 0.17% | $121.42K | New | 0.00% |
| Verition Fund Management LLC | 18,887 | 0.15% | $108.98K | – | 0.00% |
| Trexquant Investment LP | 12,339 | 0.10% | $71.20K | New | 0.00% |
| Renaissance Technologies LLC | 10,800 | 0.09% | $62.32K | −89,650 | 0.00% |
| Rockefeller Capital Management L.P. | 10,000 | 0.08% | $57.70K | – | 0.00% |
| Federation des caisses Desjardins du Quebec | 4,650 | 0.04% | $26.83K | +3,700 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 31 | 2M | 18.4% | 5 / 7 | 7 / 8 | 0M | 1M |
| Q1 2026 | 34 | 3M | 22.2% | 6 / 8 | 9 / 9 | 1M | 0M |
| Q4 2025 | 39 | 3M | 22.5% | 11 / 9 | 7 / 5 | 1M | 1M |
| Q3 2025 | 33 | 3M | 21.2% | 5 / 11 | 7 / 9 | 0M | 0M |
| Q2 2025 | 37 | 3M | 21.7% | 9 / 10 | 8 / 7 | 1M | 1M |
| Q1 2025 | 35 | 3M | 26.4% | 11 / 9 | 9 / 8 | 2M | 1M |
| Q4 2024 | 33 | 2M | 13.0% | 12 / 10 | 4 / 6 | 0M | 1M |
| Q3 2024 | 27 | 2M | 13.5% | 27 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held ALGS in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALGS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 128,770 | 1.03% | $743.00K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 46,773 | 0.37% | $269.88K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 24,809 | 0.20% | $141.41K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 16,428 | 0.13% | $94.79K | 0.01% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 8,329 | 0.07% | $35.23K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 7,553 | 0.06% | $43.05K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 6,141 | 0.05% | $35.00K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 3,573 | 0.03% | $15.11K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 3,569 | 0.03% | $20.34K | 0.00% | May 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 3,200 | 0.03% | $18.24K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 2,810 | 0.02% | $11.89K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 2,093 | 0.02% | $8.85K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 1,855 | 0.01% | $7.85K | 0.00% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 1,427 | 0.01% | $8.13K | 0.00% | May 31, 2026 |
| Dimensional US Sustainability Core 1 ETF | 1,149 | 0.01% | $4.86K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lawrence Blatt | President and CEO, Director | 1,866,092 | 14.94% | Mar 11, 2026 |
| Nikhil Aneja | Principal Accounting Officer | – | – | Mar 11, 2026 |
| Julian A. Symons | See Remarks | 394,064 | 3.16% | Mar 11, 2026 |
| Lesley Ann Calhoun | See Remarks | – | – | Mar 11, 2026 |
| Margarita Chavez | Director | – | – | Jun 29, 2026 |
| James Paul Scopa | Director | 183,083 | 1.47% | Jun 29, 2026 |
| Carole Nuechterlein | Director | 11,025,941 | 88.28% | Jun 29, 2026 |
| Heather Preston | Director | – | – | Jun 29, 2026 |
| Bridget A. Martell | Director | – | – | Jun 29, 2026 |
| Peter Hirth | Director | 59,549 | 0.48% | Jun 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lawrence Blatt Chief Executive Officer, Director | Oct 25, 2023 | Award | +610,277 | $0.76 | $463.81K | 1,847,575 |
| Carole Nuechterlein Director, 10% owner | Oct 25, 2023 | Buy | +7,933,601 | $0.76 | $6.03M | 11,025,941 |
| James Paul Scopa Director | Oct 25, 2023 | Award | +183,083 | $0.76 | $139.14K | 183,083 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +8,383 | – | – | 8,383 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −9,719 | – | – | 0 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +9,719 | – | – | 9,719 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +2,226 | – | – | 4,452 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −8,383 | – | – | 0 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −485,979 | – | – | 1,457,937 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −485,979 | – | – | 1,943,916 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +9,720 | – | – | 9,720 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −9,720 | – | – | 0 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +8,385 | – | – | 8,385 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −8,385 | – | – | 0 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +2,226 | – | – | 2,226 |
| Holdings A/S Novo 10% owner | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 2,614,563 |
| Holdings A/S Novo 10% owner | Oct 20, 2020 | Conversion | +2,414,563 | – | – | 2,414,563 |
| Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington 10% owner | Oct 20, 2020 | Conversion | +1,335,048 | – | – | 1,335,048 |
| Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington 10% owner | Oct 20, 2020 | Conversion | +571,143 | – | – | 1,906,191 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +198,485 | – | – | 662,444 |
| Thomas Woiwode Director | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 862,444 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +85,065 | – | – | 2,429,895 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +198,839 | – | – | 2,344,830 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +463,959 | – | – | 463,959 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +260,380 | – | – | 260,380 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +1,885,611 | – | – | 1,885,611 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Buy | +483,267 | $15.00 | $7.25M | 3,116,658 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +30,939 | – | – | 363,639 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +72,320 | – | – | 332,700 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Buy | +66,733 | $15.00 | $1.00M | 430,372 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +224,054 | – | – | 2,633,391 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +523,726 | – | – | 2,409,337 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +1,437 | – | – | 18,355 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +21,724 | – | – | 236,347 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +1,437 | – | – | 18,355 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +3,359 | – | – | 16,918 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +3,359 | – | – | 16,918 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +50,781 | – | – | 214,623 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +13,559 | – | – | 13,559 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +13,559 | – | – | 13,559 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +163,842 | – | – | 163,842 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +198,839 | – | – | 2,344,830 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +463,959 | – | – | 463,959 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +85,065 | – | – | 2,429,895 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +198,485 | – | – | 662,444 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 862,444 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +662,799 | – | – | 2,808,790 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +283,550 | – | – | 3,092,340 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +41,016 | – | – | 41,016 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +50,712 | – | – | 91,728 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +13,671 | – | – | 13,671 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +13,671 | – | – | 13,671 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +122,601 | – | – | 122,601 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +3,394 | – | – | 17,065 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +1,452 | – | – | 18,517 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +3,394 | – | – | 17,065 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +21,695 | – | – | 113,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aligos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,624 shares on Sep 22, 2026 over the last 90 days.
See a number that looks wrong?